It is hard to look back on something and say it failed especially if it was a US$11.7bn bet as CSL's Vifor acquisition was. But what else can you say? Impairments now total roughly US$6.5bn, the share price is barely over $100 having peaked at over $300 only a couple of years ago and the…
